01-7995. Circulatory System Devices Panel of the Medical Devices Advisory Committee; Notice of Meeting  

  • Start Preamble

    AGENCY:

    Food and Drug Administration, HHS.

    ACTION:

    Notice.

    This notice announces a forthcoming meeting of a public advisory committee of the Food and Drug Administration (FDA). The meeting will be open to the public.

    Name of Committee: Circulatory System Devices Panel of the Medical Devices Advisory Committee.

    General Function of the Committee: To provide advice and recommendations to the agency on FDA's regulatory issues.

    Date and Time: The meeting will be held on April 23, 2001, 8 a.m. to 5 p.m.

    Location: Holiday Inn, Kennedy Grand Ballroom, 8777 Georgia Ave., Silver Spring, MD.

    Contact: Megan Moynahan, Center for Devices and Radiological Health (HFZ-450), Food and Drug Administration, 9200 Corporate Blvd., Rockville, MD 20850, 301-443-8517, ext. 171, or FDA Advisory Committee Information Line, 1-800-741-8138 (301-443-0572 in the Washington, DC area), code 12625. Please call the Information Line for up-to-date information on this meeting.

    Agenda: The committee will discuss, make recommendations, and vote on a premarket approval application for a peripheral stent used in the treatment of stenotic or occluded femoral or popliteal arteries. Subsequently, the committee will discuss clinical study design issues for peripheral stents used in the treatment of stenotic or occluded iliac arteries. Background information and questions for the committee will be available to the public on April 20, 2001, on the Internet at http://www.fda.gov/​cdrh/​panelmtg.html.

    Procedure: Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. Written submissions may be made to the contact person by April 18, 2001. Oral presentations from the public will be scheduled between approximately 8 a.m. and 8:30 a.m. Near the end of the committee deliberations, a 30-minute open public session will be conducted for interested persons to address issues specific to the submission before the committee. Time allotted for each presentation may be limited. Those desiring to make formal oral presentations should notify the contact person before April 18, 2001, and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time requested to make their presentation.

    Notice of this meeting is given under the Federal Advisory Committee Act (5 U.S.C. app. 2).

    End Preamble Start Supplemental Information Start Signature

    Dated: March 26, 2001.

    Linda A. Suydam,

    Senior Associate Commissioner.

    End Signature End Supplemental Information

    [FR Doc. 01-7995 Filed 3-30-01; 8:45 am]

    BILLING CODE 4160-01-S

Document Information

Published:
04/03/2001
Department:
Food and Drug Administration
Entry Type:
Notice
Action:
Notice.
Document Number:
01-7995
Pages:
17562-17562 (1 pages)
PDF File:
01-7995.pdf